Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Regulation of experimental mucosal inflammation.

W Strober1, I Fuss, A Kitani

  • 1Mucosal Immunity Section, Laboratory of Clinical Investigation, NIAID, National Institute of Health, Bethesda, Maryland 20892-1890, USA. wstrober@niaid.nih.gov

Acta Odontologica Scandinavica
|September 26, 2001
PubMed
Summary

Controlling inflammation involves targeting T-helper 1 (Th1) immune responses. Researchers found that blocking interleukin-12 (IL-12) or using transforming growth factor-beta (TGF-beta) effectively reduces intestinal inflammation like Crohn disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunopathogenesis of pancreatitis.

Mucosal immunology·2016
Same author

Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis.

Mucosal immunology·2016
Same author

The regulation of gastrointestinal immune responses.

Immunology today·2014
Same author

NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6.

Mucosal immunology·2014
Same author

Transcription of RORγt in developing Th17 cells is regulated by E-proteins.

Mucosal immunology·2013
Same author

Nod2 deficiency is associated with an increased mucosal immunoregulatory response to commensal microorganisms.

Mucosal immunology·2013

Area of Science:

  • Immunology
  • Gastroenterology

Background:

  • Many inflammatory conditions stem from immune dysregulation, often involving Th1 or Th2 T-cell responses.
  • Crohn disease is characterized by an excessive immune response to gut bacteria, linked to Th1 abnormalities.

Purpose of the Study:

  • To investigate therapeutic strategies for controlling Th1-mediated inflammation, specifically in Crohn disease.
  • To explore the role of interleukin-12 (IL-12) and transforming growth factor-beta (TGF-beta) as therapeutic targets.

Main Methods:

  • Studied Th1 T-cell responses in murine models and human Crohn disease samples.
  • Administered anti-IL-12 agents to downregulate IL-12 secretion and induce Th1 cell apoptosis.
  • Delivered TGF-beta using intranasal DNA and gene therapy approaches in experimental intestinal inflammation models.

Related Experiment Videos

Main Results:

  • Crohn disease inflammation is associated with overproduction of IL-12, interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha).
  • Anti-IL-12 treatment significantly reduced inflammation by promoting Th1 cell apoptosis.
  • TGF-beta delivery, particularly via intranasal DNA, showed promise in treating experimental intestinal inflammation.

Conclusions:

  • Targeting Th1 immune responses, specifically IL-12 and TGF-beta pathways, offers effective therapeutic strategies for inflammatory diseases.
  • Cytokine-based therapies demonstrate potential for safe, effective, and long-lasting control of inflammation.
  • Understanding immune checkpoints provides a pathway for novel anti-inflammatory treatments.